GlassScriptPhysician profile
Neelima Ghanta
NPI 1710338611
$1,179.22
in general payments reported to CMS, 2019-2025
23 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $118 · 2024: $15.57 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $240.31 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $105.90 | 2021-2022 | |
| Dexcom, INC. | $94.03 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $90.56 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $88.81 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astellas Pharma US INC | $77.44 | 2025 | Veozah |
| Kyowa Kirin, INC. | $63.57 | 2025 | |
| Corcept Therapeutics | $46.74 | 2025 | Korlym |
| Insulet Corporation | $43.74 | 2021 | |
| Tandem Diabetes Care, INC. | $41.08 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $35.37 | 2025 | |
| Amgen INC. | $30.84 | 2025 | Evenity |
| Abbvie INC. | $29.71 | 2025 | |
| Axsome Therapeutics, INC. | $27.24 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $24.86 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $23.44 | 2021 | |
| Averitas Pharma INC. | $20.17 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $19.66 | 2025 | |
| Ibsa Pharma INC. | $18.29 | 2025 | Tirosint, Flector, Licart |
| Esperion Therapeutics, INC. | $15.66 | 2025 | Nexletol |
| Medtronic, INC. | $15.57 | 2024 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $15.23 | 2025 | Zoryve |
| Cequr Corporation | $11.00 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelima Ghanta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.